PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
15305185-2	2004	ZD6474 is a potent inhibitor of VEGF-R2 tyrosine kinase activity, but with additional inhibitory effects on other growth factors.	vandetanib	0-6	vascular endothelial growth factor A	Rattus norvegicus	32-36	
31164986-1	2019	Vandetanib and pazopanib are clinically available, multi-targeted inhibitors of vascular endothelial growth factor (VEGF) and platelet-derived growth factor (PDGF) receptor tyrosine kinases.	vandetanib	0-10	vascular endothelial growth factor A	Rattus norvegicus	80-114	
31164986-1	2019	Vandetanib and pazopanib are clinically available, multi-targeted inhibitors of vascular endothelial growth factor (VEGF) and platelet-derived growth factor (PDGF) receptor tyrosine kinases.	vandetanib	0-10	vascular endothelial growth factor A	Rattus norvegicus	116-120	
20811710-3	2010	Vandetanib (ZD6474) is mainly a vascular endothelial growth factor (VEGF) and epidermal growth factor (EGF) receptor tyrosine kinase inhibitor.	vandetanib	0-10	vascular endothelial growth factor A	Rattus norvegicus	32-66	
20811710-3	2010	Vandetanib (ZD6474) is mainly a vascular endothelial growth factor (VEGF) and epidermal growth factor (EGF) receptor tyrosine kinase inhibitor.	vandetanib	0-10	vascular endothelial growth factor A	Rattus norvegicus	68-72	
20811710-3	2010	Vandetanib (ZD6474) is mainly a vascular endothelial growth factor (VEGF) and epidermal growth factor (EGF) receptor tyrosine kinase inhibitor.	vandetanib	12-18	vascular endothelial growth factor A	Rattus norvegicus	32-66	
20811710-3	2010	Vandetanib (ZD6474) is mainly a vascular endothelial growth factor (VEGF) and epidermal growth factor (EGF) receptor tyrosine kinase inhibitor.	vandetanib	12-18	vascular endothelial growth factor A	Rattus norvegicus	68-72	
18228115-2	2008	The effect of ZD6474, a potent inhibitor of VEGF-receptor-2, was evaluated in combination with either radiotherapy or temozolomide.	vandetanib	14-20	vascular endothelial growth factor A	Rattus norvegicus	44-48	
30687018-7	2018	Pharmacological inhibition of VEGF signaling by oral application of a tyrosine kinase inhibitor (Vandetanib) prevented the recovery of spatial and visual memory in animals housed in EE, along with an increase in apoptosis and a reduction in neurogenesis.	vandetanib	97-107	vascular endothelial growth factor A	Rattus norvegicus	30-34	
12183421-5	2002	Selective inhibition of VEGF signaling has been demonstrated in vivo in a growth factor-induced hypotension model in anesthetized rat: administration of ZD6474 (2.5 mg/kg, i.v.)	vandetanib	153-159	vascular endothelial growth factor A	Rattus norvegicus	24-28	
12183421-7	2002	Once-daily oral administration of ZD6474 to growing rats for 14 days produced a dose-dependent increase in the femoro-tibial epiphyseal growth plate zone of hypertrophy, which is consistent with inhibition of VEGF signaling and angiogenesis in vivo.	vandetanib	34-40	vascular endothelial growth factor A	Rattus norvegicus	209-213